Roche Investor Update: Gazyva /Gazyvaro (obinutuzumab) in Phase III study iLLUMINATE - partner update Freitag, 25. Mai 2018 - 17:56

Gazyva /Gazyvaro (obinutuzumab) in Phase III study iLLUMINATE - partner update

Dear Investor, Please find a link to a recent release from one of our partners, Abbvie, regarding a topline read out of the Phase III study iLLUMINATE testing Gazyva /Gazyvaro (obinutuzumab) plus Imbruvica (ibrutinib) iLLUMINATE press release We hope you find this information useful. With best regards,

Roche Investor Relations

Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com

Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com

Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com

Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

Dr. Susann Manchado
Phone: +41 61-68-75619
e-mail: susann.manchado@roche.com

Investor Relations North America

Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com